MILAN, Italy, May 03, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announced the presentation of the clinical trial design of the Company’s lead program in Usher 1B by the program’s Principal Investigator, Prof. Francesca Simonelli, at…
Wed, 15 May 2024 06:28:00 GMT Additional information is available at www.ivfh.com. Forward-Looking Statements This release contains certain forward-looking statements and information relating to Innovative Food Holdings, Inc. (the ...
Fri, 03 May 2024 09:35:00 GMT MILAN, Italy, May 3, 2024 — AAVantgarde Bio (AAVantgarde), a clinical-stage ... design of this first-in-human Phase 1/2 clinical study at the Summit. Through this innovative design, we aim to ...
Fri, 03 May 2024 02:35:00 GMT MILAN, Italy, May 03, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde ... Phase 1/2 clinical study at the Summit. Through this innovative design, we aim to revolutionize our approach ...
Thu, 02 May 2024 01:30:00 GMT Combining IDW’s innovative business model, which offers best-in-class cold drink equipment, with Cantaloupe’s forward-thinking solutions, is ideally suited to fuel the next phase of growth and ...
Wed, 01 May 2024 09:00:00 GMT EXTON, Pa.--(BUSINESS WIRE)-- Innovative Solutions & Support, Inc. (the "Company") (NASDAQ: ISSC) today announced it will release second quarter of fiscal 2024 financial results on Monday ...
